相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial
Christopher Parker et al.
EUROPEAN JOURNAL OF CANCER (2017)
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
Philip Cornford et al.
EUROPEAN UROLOGY (2017)
Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases
R. McKay et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models
Mari I. Suominen et al.
CLINICAL CANCER RESEARCH (2017)
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223
O. Sartor et al.
ANNALS OF ONCOLOGY (2017)
Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial
Nicholas J. Vogelzang et al.
CLINICAL GENITOURINARY CANCER (2017)
F39Radium-223 alpha emitter agent in safety study in mCRPC popUlation for long-teRm evaluation (REASSURE)
C.N. Sternberg et al.
ANNALS OF ONCOLOGY (2016)
Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
Keisuke Yoshida et al.
ANNALS OF NUCLEAR MEDICINE (2016)
A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative hormone receptor-positive breast cancer and bone metastases
H. Rugo et al.
ANNALS OF ONCOLOGY (2016)
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
S. Nilsson et al.
ANNALS OF ONCOLOGY (2016)
Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial
Christopher Parker et al.
EUROPEAN UROLOGY (2016)
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer
Susan Halabi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015
William T. Lowrance et al.
JOURNAL OF UROLOGY (2016)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James et al.
LANCET (2016)
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
Fred Saad et al.
LANCET ONCOLOGY (2016)
The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone
Jean A. McDougall et al.
ONCOLOGIST (2016)
Chemotherapy Following Radium-223 Dichloride Treatment in ALSYMPCA
Oliver Sartor et al.
PROSTATE (2016)
Advances in the management of castration resistant prostate cancer
Chad R. Ritch et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Advances in the management of castration resistant prostate cancer
Chad R. Ritch et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
Douglas G. McNeel et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)
Fred Saad et al.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2015)
3-year safety yellow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA
Chris Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting.
A. Oliver Sartor et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Randomized Exercise Trial of Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors
Melinda L. Irwin et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases
Sarah J. Chittenden et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al.
LANCET ONCOLOGY (2015)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients
Andrew J. Lloyd et al.
VALUE IN HEALTH (2015)
Revision of the NIST Standard for 223Ra: New Measurements and Review of 2008 Data
B. E. Zimmerman et al.
JOURNAL OF RESEARCH OF THE NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY (2015)
A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
Daniel Peter Petrylak et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline
Ethan Basch et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
Peter Hoskin et al.
LANCET ONCOLOGY (2014)
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
Oliver Sartor et al.
LANCET ONCOLOGY (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer
Jorge A. Carrasquillo et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer
Christopher C. Parker et al.
EUROPEAN UROLOGY (2013)
2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
Pirkko-Liisa Kellokumpu-Lehtinen et al.
LANCET ONCOLOGY (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
S. Nilsson et al.
EUROPEAN JOURNAL OF CANCER (2012)
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi et al.
LANCET ONCOLOGY (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Characterising the castration-resistant prostate cancer population: a systematic review
M. Kirby et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006
N. Sathiakumar et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2011)
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer:: a randomised, multicentre, placebo-controlled phase II study
Sten Nilsson et al.
LANCET ONCOLOGY (2007)
High-linear energy transfer irradiation targeted to skeletal metastases by the α-emitter 223Ra:: Adjuvant or alternative to conventional modalities?
Oyvind S. Bruland et al.
CLINICAL CANCER RESEARCH (2006)
First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases
S Nilsson et al.
CLINICAL CANCER RESEARCH (2005)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Metastatic patterns of prostate cancer:: An autopsy study of 1,589 patients
L Bubendorf et al.
HUMAN PATHOLOGY (2000)
分享论文
